Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118299) titled 'Clinical Study on FBLN3-Induced Gemcitabine Resistance in Pancreatic Cancer' on Feb. 4.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
Condition:
Pancreatic Ductal Adenocarcinoma (PDAC)
Recruitment Status: Recruiting
Phase: Retrospective study
Date of First Enrollment: 2025-11-14
Target Sample Size: Based on the response to gemcitabine chemotherapy, patients are divided into Gemcitabine-Resistant Group and Gemcitabine-Sensitive Group:35;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj...